HighTower Advisors LLC boosted its position in shares of Stryker Corporation (NYSE:SYK – Free Report) by 4.0% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 505,357 shares of the medical technology company’s stock after purchasing an additional 19,352 shares during the period. HighTower Advisors LLC’s holdings in Stryker were worth $139,170,000 at the end of the most recent quarter.
Other institutional investors have also recently added to or reduced their stakes in the company. State Street Corp grew its stake in Stryker by 1.2% during the second quarter. State Street Corp now owns 15,532,565 shares of the medical technology company’s stock worth $4,903,772,000 after buying an additional 183,400 shares during the last quarter. Wellington Management Group LLP increased its holdings in shares of Stryker by 0.6% during the second quarter. Wellington Management Group LLP now owns 8,167,185 shares of the medical technology company’s stock worth $2,571,357,000 after buying an additional 45,478 shares in the last quarter. Bank of America Corp DE acquired a new stake in shares of Stryker during the second quarter worth approximately $1,404,284,000. Royal Bank of Canada increased its holdings in shares of Stryker by 6.5% during the first quarter. Royal Bank of Canada now owns 3,273,232 shares of the medical technology company’s stock worth $1,075,552,000 after buying an additional 199,863 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in shares of Stryker by 21.8% in the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 2,689,376 shares of the medical technology company’s stock valued at $846,723,000 after acquiring an additional 481,175 shares during the last quarter. 77.09% of the stock is owned by institutional investors.
Wall Street Analysts Forecast Growth
SYK has been the topic of several recent analyst reports. UBS Group reduced their target price on Stryker from $400.00 to $382.00 and set a “buy” rating on the stock in a report on Monday, August 3rd. Wolfe Research lowered Stryker from an “outperform” rating to a “peer perform” rating in a research report on Thursday, August 13th. BMO Capital Markets reaffirmed an “outperform” rating and set a $309.00 price target (down from $317.00) on shares of Stryker in a report on Friday, October 30th. Canaccord Genuity Group downgraded Stryker from a “buy” rating to a “hold” rating and cut their price objective for the company from $385.00 to $300.00 in a research report on Friday, October 30th. Finally, JPMorgan Chase & Co. reduced their price objective on Stryker from $350.00 to $340.00 and set an “overweight” rating on the stock in a research note on Friday, October 30th. Twenty-one research analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company. According to MarketBeat.com, Stryker currently has an average rating of “Moderate Buy” and a consensus price target of $342.19.
View Our Latest Stock Analysis on Stryker
Insider Activity at Stryker
In related news, insider Dylan Crotty sold 441 shares of the business’s stock in a transaction that occurred on Friday, August 21st. The shares were sold at an average price of $328.61, for a total value of $144,917.01. Following the completion of the transaction, the insider owned 6,102 shares in the company, valued at $2,005,178.22. The trade was a 6.74% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Ronda E. Stryker sold 550,000 shares of the company’s stock in a transaction on Friday, November 6th. The stock was sold at an average price of $325.32, for a total value of $178,926,000.00. Following the transaction, the director directly owned 1,701,375 shares in the company, valued at approximately $553,491,315. This represents a 24.43% decrease in their position. The SEC filing for this sale provides additional information. 4.60% of the stock is owned by corporate insiders.
Stryker Stock Up 2.1%
Shares of NYSE:SYK opened at $317.20 on Wednesday. Stryker Corporation has a 12 month low of $267.00 and a 12 month high of $389.33. The company’s 50-day moving average price is $293.26 and its two-hundred day moving average price is $322.17. The company has a quick ratio of 1.30, a current ratio of 2.18 and a debt-to-equity ratio of 0.60. The firm has a market cap of $120.76 billion, a P/E ratio of 33.78, a P/E/G ratio of 2.13 and a beta of 0.78.
Stryker (NYSE:SYK – Get Free Report) last posted its quarterly earnings data on Thursday, October 29th. The medical technology company reported $3.52 earnings per share for the quarter, missing the consensus estimate of $3.55 by ($0.03). Stryker had a net margin of 13.78% and a return on equity of 23.74%. The company had revenue of $6.52 billion during the quarter, compared to analyst estimates of $6.62 billion. During the same quarter in the previous year, the business posted $3.19 EPS. The company’s revenue was up 7.6% compared to the same quarter last year. As a group, research analysts forecast that Stryker Corporation will post 14.85 EPS for the current fiscal year.
Stryker Profile
Stryker is a medical technology company that develops and sells products and services for healthcare providers. Its offerings include orthopedic implants and surgical equipment, neurotechnology and spine products, and medical and surgical equipment used in hospitals and other care settings. The company’s products also include patient-handling and emergency medical equipment, as well as instruments and technologies that support surgical procedures. Stryker serves healthcare customers in the United States and internationally.
Read More
- Five stocks we like better than Stryker
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK – Free Report).
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.
